USA - engelsk - NLM (National Library of Medicine)

lupin limited - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets usp are indicated for the treatment of adult and pediatric patients (13 years and older) with m

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non-β-lactamase–producing strains only). limitations of use the effectiveness of cefuroxime axetil for sinus infections caused by β-lactamase–producing haemoph

USA - engelsk - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes. limitations of use - the efficacy of cefuroxime axetil in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae , haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indica

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-mode

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use - the efficacy of cefuroxime axetil tablets in the prevention of rheumatic fever was not established in clinical trials. - the efficacy of cefuroxime axetil tablets in the treatment of penicillin-resistant strains of streptococcus pyogenes has not been demonstrated in clinical trials. cefuroxime axetil tablets are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae, haemophilus influenzae (including β-lactamase–producing strains), moraxella catarrhalis (including β-lactamase–producing strains), or streptococcus pyogenes . cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-mode

USA - engelsk - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets, usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use cefuroxime axetil tablets, usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus  pneumoniae , haemophilus influenzae (including β- lactamase-producing strains), moraxella catarrhalis (including β- lactamase-producing strains), or streptococcus pyogenes. cefuroxime axetil tablets, usp are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non- β-lactamase-producing strains only). limitations of use the effectiveness of cefuroxime axetil tablets, usp for sinus infections caused

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cefuroxime sodium 1578mg equivalent to cefuroxime 1500 mg;   - powder for injection - 1.5 g - active: cefuroxime sodium 1578mg equivalent to cefuroxime 1500 mg   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include:

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cefuroxime sodium 789mg equivalent to cefuroxime 750 mg;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to cefuroxime 750 mg   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include:

USA - engelsk - NLM (National Library of Medicine)

stat rx usa llc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 500 mg - note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil tablets: cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1.   pharyngitis/tonsillitis caused by streptococcus pyogenes.      note : the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. th

Canada - engelsk - Health Canada

fresenius kabi canada ltd - cefuroxime (cefuroxime sodium) - powder for solution - 750mg - cefuroxime (cefuroxime sodium) 750mg - second generation cephalosporins